- Research Article
1
- 10.12659/ajcr.950650
Long-Term Outcome of Isolated Duodenal Transit Bipartition as Initial Metabolic Surgery: A 19-Year Follow-Up Case Report
- Jan 12, 2026
- The American Journal of Case Reports
- Paulo Reis Rizzo Esselin De Melo + 32 more +32
Patient: Female, 40-year-oldFinal Diagnosis: ObesitySymptoms: ObesityClinical Procedure: —Specialty: SurgeryObjective: Unusual clinical courseBackgroundMetabolic and bariatric surgeries (MBS) are effective treatments for obesity and related comorbidities, such as diabetes and hypertension. In patients with morbid obesity and challenges like hepatomegaly, conventional procedures may increase risks. Staged MBS was developed to address these issues, enhancing safety. This report highlights the successful use of isolated intestinal transit bipartition with duodeno-ileal anastomosis, preserving the duodenum, as the first stage of the duodenal switch.Case ReportA 40-year-old woman with a BMI of 40.2 kg/m2 was booked for MBS. Severe hepatomegaly impaired safe access to the esophagogastric junction, leading to the performance of only the intestinal stage of the duodenal switch. A duodeno-ileal anastomosis was created 250 cm from the ileocecal valve, preserving the stomach and partial duodenal function. Without the gastric stage, the patient achieved 50 kg of weight loss (equivalent to 78.7% excess weight loss) over 19 years, without requiring additional surgery. Minor complications included occasional diarrhea, meteorism, and difficulties with vitamin supplementation, all managed effectively through dietary adjustments and nutritional guidance. A benefit was increased satiety.ConclusionsIsolated intestinal transit bipartition with duodeno-ileal anastomosis is an approach that may be used in exceptional cases, such as with this patient. Despite the favorable long-term follow-up results, further studies are necessary to better understand this approach. This method demonstrated sustained weight loss and long-term metabolic control, potentially representing a promising initial treatment option for patients with lower BMIs, including those with type 2 diabetes.
Read more